Neuren Pharmaceuticals Limited
NURPF · OTC
Market closed$13.46$0.00 (0.00%)After hours $13.46 · 0.00%
Key statistics
Previous close$13.46
Open$12.00
Day high$13.46
Day low$12.00
52-week high$14.80
52-week low$7.70
Market cap1.71B
Volume250.00
Average volume40.00
P/E ratio86.64
Forward P/E—
EPS0.16
Dividend yield0.00%
Market context
Why it moved
NURPF saw no significant price movement today, remaining flat as no major company-specific news or catalysts were identified to drive meaningful trading activity, with only minimal volume recorded.
What is happening
Recent company-specific developments and publisher coverage.
Simply Wall Street · July 15, 2026How Investors Are Reacting To Neuren Pharmaceuticals (ASX:NEU) Larger-Than-Expected Phelan-McDermid Syndrome Population EstimateMoomoo · June 30, 2026Neuren Pharmaceuticals's Earnings Boosted by EU U-Turn on Trofinetide -- Market TalkMoomoo · June 29, 2026Neuren Pharmaceuticals Price Target Raised 6.8% to A$23.50/Share by Bell PotterTradingView · February 11, 2026Neuren Pharmaceuticals Announces New On-Market Share Buy-Back Program Mt Newswire · June 29, 2026Jefferies Maintains Neuren Pharmaceuticals' Daybue Royalty Timeline Mt Newswire · June 29, 2026Update: Neuren Pharmaceuticals Secures Positive Recommendation for Daybue From EMA Committee; Shares Up 29% Mt Newswire · June 28, 2026Neuren Pharmaceuticals Secures Positive Recommendation for Daybue From EMA Committee Mt Newswire · May 7, 2026Neuren Pharmaceuticals' Nasdaq-Listed Partner Reports 20% Increase in Q1 Net Sales of Rett Syndrome Drug; Shares Up 3% Mt Newswire · April 8, 2026Neuren Pharmaceuticals Says Rett Syndrome Drug DAYBUE STIX Widely Available in the US Mt Newswire · March 2, 2026Neuren Partner Plans to Request Re-examination of European Authority's Opinion on Trofinetide Marketing Authorization Application Mt Newswire · February 27, 2026Neuren Pharmaceuticals Posts Lower 2025 Earnings, Revenue Mt Newswire · February 26, 2026Neuren Pharmaceuticals Says US Partner Reports Higher Q4 2025 Daybue Sales; Shares Up 6%